Spain

Latest:

CGRP antagonists 5 years on – what has been learned?TANDEM trial supports efficacy of dual therapy with ubrogepant and atogepant Do CGRP mAbs act centrally as well as peripherally?European registries show comparable CGRP mAb efficacy to clinical trials Galcanezumab superior to amitriptyline and topiramate Aquipta (atogepant) receives EU approval for migraine prevention PROGRESS results for atogepant in chronic migraine published CGRP mAbs show efficacy in vestibular migraine

Patients respond to anti-CGRP mAbs irrespective of previous botulinum toxin A effects

In complex patients with multiple treatment failures, good responder rates are seen with anti-CGRP mAbs irrespective of previous poor response to botulinum toxin A (BTX-A), but dual therapy with anti-CGRP mAbs and botulinum toxin A does not appear to add more benefit compared to anti-CGRP mAb monotherapy.1 These were the findings from a real world …

Educational Partners and Supporters (others pending)

This program is funded in part via an independent educational grant from AbbVie

Editorial PolicyCGRP Forum is an expert resource for clinicians and healthcare professionals working with migraine patients. All patients should discuss their medication with their healthcare professional. Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Patients respond to anti-CGRP mAbs irrespective of previous botulinum toxin A effects

Trials

Meeting Reports

Resources